Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.46 |
| ▸ | ITGAV | P06756 | 7/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KYNU | Q16719 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092077 | 1.00 | TGM2 (0.67) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL1091730 | 0.91 | TGM2 (0.65) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL14567037 | 0.91 | TGM2 (0.65) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL1091729 | 0.91 | TGM2 (0.65) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL1091728 | 0.91 | TGM2 (0.65) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL12145564 | 0.91 | TGM2 (0.55) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL1091635 | 0.89 | TGM2 (0.73) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL1091637 | 0.89 | TGM2 (0.73) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL5483795 | 0.89 | TGM2 (0.73) | TGM2ITGB3ITGAVITGA2BCYP1A2 | |
| SCHEMBL10413271 | 0.86 | TGM2 (0.63) | TGM2ITGB3ITGAVITGA2BKYNU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-11-24 | — | — | US | claimed |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; AND THE WASHINGTON UNIVERSITY | 2009-12-17 | — | — | US | claimed |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-02-12 | — | — | US | claimed |
| EP-1931205-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-18 | — | — | EP | claimed |
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-02-21 | — | — | US | claimed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | claimed |
| JP-2007511607-A | — | — | 2007-05-10 | — | — | JP | claimed |
| WO-2007025247-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | claimed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | claimed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | claimed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | claimed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | claimed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8470782-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-06-25 | — | — | US | disclosed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | disclosed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | TGM2 13/4885ITGB3 3613/4885ITGAV 3154/4885 |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | TGM2 1/4885ITGB3 1426/4885ITGAV 2287/4885 |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885ITGB3 3613/4885ITGAV 3154/4885 |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | MGMT, GMFG, HNMT | TGM2 5/4885ITGB3 3863/4885ITGAV 4169/4885 |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885ITGB3 3613/4885ITGAV 3154/4885 |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | TGM2, TGM3, TGM1 | TGM2 1/4885ITGB3 1426/4885ITGAV 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.